Description

Levicitam 250 Coated Tablets 250 mg. №30

Ingredients:

Levicitam 250 tablets contain 250 mg of Levetiracetam as the active ingredient. Other ingredients include microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, and magnesium stearate.

Dosage:

The recommended dosage of Levicitam 250 is determined by a healthcare provider based on individual factors. Typically, the starting dose is 500 mg twice daily, which can be adjusted as needed. It is important to follow the prescribed dosage and administration instructions.

Indications:

Levicitam 250 is indicated for the treatment of epilepsy in adults and children. It is used as an adjunctive therapy in the management of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures.

Contraindications:

Levicitam 250 is contraindicated in patients with a known hypersensitivity to Levetiracetam or any of the tablet’s components. It is important to consult a healthcare provider before starting this medication to ensure it is safe and appropriate for use.

Directions:

Levicitam 250 tablets should be taken orally with or without food as directed by a healthcare provider. The tablets should not be chewed or crushed. It is important to adhere to the prescribed dosage and frequency to achieve optimal therapeutic effects.

Scientific Evidence:

Several studies have demonstrated the efficacy of Levetiracetam in the management of epilepsy. A study by French et al. (2001) showed that Levetiracetam was effective as an add-on therapy for refractory partial seizures, with a significant reduction in seizure frequency compared to a placebo. Additionally, a meta-analysis by Glauser et al. (2013) supported the use of Levetiracetam in both adults and children with epilepsy.

Additional Information:

In clinical trials, Levicitam 250 has been well-tolerated with a favorable safety profile. Common side effects may include dizziness, drowsiness, and fatigue. It is important to report any unusual or severe side effects to a healthcare provider. Patients should not discontinue the medication abruptly without medical advice.

Levicitam 250 offers a convenient once-daily dosing option for individuals requiring adjunctive therapy for epilepsy. Its mechanism of action involves binding to synaptic vesicle protein 2A (SV2A), which modulates neurotransmitter release and helps stabilize neuronal excitability. This unique mechanism differentiates Levetiracetam from traditional antiepileptic drugs, making it a valuable treatment option for patients with epilepsy.